{"log_id": 781773669632490215, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 1.2e-05, "average": 0.998064, "min": 0.983013}, "location": {"width": 660, "top": 194, "height": 48, "left": 159}, "words": "对年龄小于18岁的患者进行的安全性和有效性研究的治疗期尚未超过2年"}, {"probability": {"variance": 2e-06, "average": 0.998372, "min": 0.996042}, "location": {"width": 113, "top": 287, "height": 26, "left": 168}, "words": "【老年用药】"}, {"probability": {"variance": 0.03299, "average": 0.742963, "min": 0.610834}, "location": {"width": 34, "top": 189, "height": 138, "left": 1083}, "words": "管了章"}, {"probability": {"variance": 4.5e-05, "average": 0.997149, "min": 0.96112}, "location": {"width": 766, "top": 305, "height": 49, "left": 162}, "words": "临床研究证明了本品在两个年龄组(65岁以上和65岁以下)患者中的有效性和耐受性"}, {"probability": {"variance": 0.000316, "average": 0.994431, "min": 0.894593}, "location": {"width": 786, "top": 344, "height": 48, "left": 163}, "words": "在老年患者(>65岁)中治疗应答增强,而且没有耐受性下降的证据,因此不需要调整剂"}, {"probability": {"variance": 0, "average": 0.997286, "min": 0.997286}, "location": {"width": 22, "top": 407, "height": 22, "left": 165}, "words": "量"}, {"probability": {"variance": 0.002451, "average": 0.979768, "min": 0.848883}, "location": {"width": 155, "top": 478, "height": 26, "left": 172}, "words": "【药物相互作用】"}, {"probability": {"variance": 0, "average": 0.999897, "min": 0.999871}, "location": {"width": 46, "top": 520, "height": 23, "left": 164}, "words": "食物"}, {"probability": {"variance": 0.000287, "average": 0.993535, "min": 0.903381}, "location": {"width": 792, "top": 535, "height": 49, "left": 166}, "words": "晚餐时或晚餐后4小时服用氟伐他汀,其降血脂作用无明显差异。没有发现氟伐他汀与其"}, {"probability": {"variance": 3.2e-05, "average": 0.995601, "min": 0.981721}, "location": {"width": 413, "top": 583, "height": 41, "left": 167}, "words": "他CYP3A4底物(包括西柚汁)之间相互作用"}, {"probability": {"variance": 3e-06, "average": 0.99818, "min": 0.995136}, "location": {"width": 123, "top": 672, "height": 27, "left": 169}, "words": "药物相互作用"}, {"probability": {"variance": 2e-06, "average": 0.998966, "min": 0.9957}, "location": {"width": 249, "top": 705, "height": 34, "left": 169}, "words": "其他药物对氟伐他汀的影响"}, {"probability": {"variance": 0, "average": 0.999289, "min": 0.9979}, "location": {"width": 164, "top": 748, "height": 26, "left": 171}, "words": "贝特类药物和烟酸"}, {"probability": {"variance": 2e-06, "average": 0.998767, "min": 0.994005}, "location": {"width": 792, "top": 765, "height": 50, "left": 170}, "words": "氟伐他汀分别和苯扎贝特、吉非贝齐、环丙贝特或烟酸联合使用,氟伐他汀或其他降脂类"}, {"probability": {"variance": 0.007302, "average": 0.975069, "min": 0.531568}, "location": {"width": 794, "top": 802, "height": 53, "left": 169}, "words": "药物的生物利用度无临床意义的变化。考虑到其他HMG-CoA还原酶抑制剂和上述药物联"}, {"probability": {"variance": 4.3e-05, "average": 0.996793, "min": 0.964108}, "location": {"width": 773, "top": 841, "height": 51, "left": 172}, "words": "合应用时,发生肌病的风险增加,氟伐他汀和上述药物联合应用时亦需慎重(见注意事"}, {"probability": {"variance": 0, "average": 0.999633, "min": 0.999633}, "location": {"width": 22, "top": 906, "height": 22, "left": 175}, "words": "项"}, {"probability": {"variance": 1.7e-05, "average": 0.998201, "min": 0.98716}, "location": {"width": 168, "top": 976, "height": 30, "left": 173}, "words": "伊曲康唑和红霉素"}, {"probability": {"variance": 0.000475, "average": 0.993198, "min": 0.855706}, "location": {"width": 804, "top": 994, "height": 51, "left": 174}, "words": "氟伐他汀与细胞色素P450(CYP)3A4的强效抑制剂伊曲康唑和红霉素同时应用,对氟伐"}, {"probability": {"variance": 0.000198, "average": 0.995271, "min": 0.92209}, "location": {"width": 792, "top": 1032, "height": 52, "left": 176}, "words": "他汀生物利用度的影响很少。因为氟伐他汀与此酶的关系很小,因此推断其他的CYP3A4"}, {"probability": {"variance": 0.002475, "average": 0.983566, "min": 0.694913}, "location": {"width": 789, "top": 1070, "height": 53, "left": 176}, "words": "抑制剂如酮康唑,环孢素等不会影响氟伐他汀的生物利用度。CYP2C9同工酶在氟伐他汀"}, {"probability": {"variance": 5.7e-05, "average": 0.995215, "min": 0.960166}, "location": {"width": 718, "top": 1112, "height": 48, "left": 177}, "words": "的代谢过程中起主要的作用(约75%),而CYP2C8和CYP3A4起到的作用较小"}, {"probability": {"variance": 1.7e-05, "average": 0.995852, "min": 0.990145}, "location": {"width": 65, "top": 1188, "height": 23, "left": 178}, "words": "氟康唑"}, {"probability": {"variance": 0.002102, "average": 0.982881, "min": 0.782981}, "location": {"width": 802, "top": 1203, "height": 54, "left": 178}, "words": "在预先服用氟康唑(CYP2C9抑制剂)的健康志愿者中使用氟伐他汀后,可导致氟伐他汀"}, {"probability": {"variance": 0.000401, "average": 0.992017, "min": 0.891592}, "location": {"width": 807, "top": 1235, "height": 52, "left": 179}, "words": "的暴露量和血药浓度峰值分别升高了约84%和44%。尽管尚未发现服用氟伐他汀后在临床"}, {"probability": {"variance": 5.1e-05, "average": 0.996196, "min": 0.965577}, "location": {"width": 429, "top": 1278, "height": 39, "left": 180}, "words": "上的安全性发生改变,二者联合应用时亦需慎重"}, {"probability": {"variance": 0.021008, "average": 0.896845, "min": 0.676939}, "location": {"width": 134, "top": 1259, "height": 63, "left": 630}, "words": "诺华制药有限"}, {"probability": {"variance": 2e-06, "average": 0.997771, "min": 0.995946}, "location": {"width": 67, "top": 1292, "height": 44, "left": 692}, "words": "州分公"}, {"probability": {"variance": 0, "average": 0.999771, "min": 0.999479}, "location": {"width": 64, "top": 1356, "height": 23, "left": 181}, "words": "环孢素"}, {"probability": {"variance": 3e-06, "average": 0.998578, "min": 0.991616}, "location": {"width": 721, "top": 1372, "height": 48, "left": 195}, "words": "项研究表明,对在稳定的环孢素治疗的肾移植患者中使用本品,氟伐他汀暴露量"}, {"probability": {"variance": 0.001431, "average": 0.986506, "min": 0.821657}, "location": {"width": 780, "top": 1408, "height": 51, "left": 195}, "words": "(AUC)和最大血药浓度(Cmax)与健康受试者的历史数据相比增加了2倍。尽管这些增"}, {"probability": {"variance": 0.000185, "average": 0.993411, "min": 0.934574}, "location": {"width": 541, "top": 1454, "height": 41, "left": 183}, "words": "加并无显著临床意义,二者联合应用时应慎重(见注意事项)"}], "language": 3}